Over the past decade, pharmaceutical firms have been giving oncologists the choice to combine several drugs used in cancer treatment in order to battle even the most resistant of cancer cells. This move has been proven successful in some types of cancer, prompting pharmaceutical manufacturers to supply consistent, quality-controlled active pharmaceutical ingredients (API’s), such as Temsirolimus CAS# 162635-04-3.
These days, oncologists are employing combination therapy with the primary goal of complete cancer remission, and with the secondary aim to minimize the undesirable side-effects, mostly associated with high doses of a single chemotherapeutic agent. These include but are not limited to loss of hair, appetite, and energy. It’s effects like these that results in patients opting to skip out on some cycles of their prescribed chemotherapy regimen. In cases like these, noncompliance starts a chain of clinical complications in a fight that already appears to be a losing battle. The brief lapse of therapy allows cancer cells to grow and develop resistance to the present chemotherapeutic agent being used to target them. Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and colleagues, published important findings in the Molecular Cancer Research suggesting that increased expression of a gene called SIRT1 in cancer cells plays a significant role in the development of resistance to the chemotherapy drug, Cisplatin. The SIRT1 gene, which regulates several important cellular processes, including nutrient use and metabolism, appears to contribute to the development of Cisplatin resistance by reducing the uptake and use of glucose by cells and by altering the function of their mitochondria, which are cellular structures that produce most of the energy in cells.
Another notable study in cancer research resulted in the formulation of the drug, Temsirolimus. Temsirolimus CAS# 162635-04-3 is a drug that has gained popularity in the treatment of advanced renal cell carcinoma. Janice Dutcher, MD, presented a study during the American Society of Clinical Oncology (ASCO) 43rd Annual Meeting where Temsirolimus was found to increase cancer survival by 49% when compared to IFN-α alone. Several investigators have since then tested Temsirolimus for cancers other than renal cell carcinoma. Results of the phase 2 of the GIMEMA study found that Temsirolimus combined with Clofarabine can be safely administered to elderly patients with advanced acute myeloid leukemia. Furthermore, Temsirolimus has been found to have good results when used in the treatment of mantle cell leukemia, B-cell Non-Hodgkin Lymphoma, metastatic endometrial carcinoma and osteosarcoma.
These studies have convinced LGM Pharma to provide a comprehensive and consistent supply of active pharmaceutical ingredients (such as Temsirolimus CAS# 162635-04-3 and Clofarabine CAS # 123318-82-1) to pharmaceutical companies actively involved in cancer research. The company meets its clients’ needs and at the same time fulfills its mission of providing quality APIs for the improvement of mankind’s quality of life.
*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.